Table of Content
1. Report Introduction
2. Ataxia Telangiectasia (AT) Market Overview at a Glance
2.1. Market Share Distribution of Ataxia Telangiectasia (AT) in 2017
2.2. Market Share Distribution of Ataxia Telangiectasia (AT) in 2028
3. Disease Background and Overview: Ataxia Telangiectasia (AT)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Ataxia Telangiectasia (AT) in 7MM
4.3. Total Prevalent Patient Population of Ataxia Telangiectasia (AT) in 7MM – By Countries
5. Epidemiology of Ataxia Telangiectasia (AT) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Ataxia Telangiectasia (AT)
5.1.3. Sub-Type Specific cases of the Ataxia Telangiectasia (AT) *Indication Specific
5.1.4. Sex- Specific Cases of the Ataxia Telangiectasia (AT) *Indication Specific
5.1.5. Diagnosed Cases of the Ataxia Telangiectasia (AT)
5.1.6. Treatable Cases of the Ataxia Telangiectasia (AT)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Ataxia Telangiectasia (AT)
5.4.3. Sub-Type Specific cases of the Ataxia Telangiectasia (AT) *
5.4.4. Sex- Specific Cases of the Ataxia Telangiectasia (AT) *
5.4.5. Diagnosed Cases of the Ataxia Telangiectasia (AT)
5.4.6. Treatable Cases of the Ataxia Telangiectasia (AT)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Ataxia Telangiectasia (AT)
5.5.3. Sub-Type Specific cases of the Ataxia Telangiectasia (AT) *
5.5.4. Sex- Specific Cases of the Ataxia Telangiectasia (AT) *
5.5.5. Diagnosed Cases of the Ataxia Telangiectasia (AT)
5.5.6. Treatable Cases of the Ataxia Telangiectasia (AT)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Ataxia Telangiectasia (AT)
5.6.3. Sub-Type Specific cases of the Ataxia Telangiectasia (AT) *
5.6.4. Sex- Specific Cases of the Ataxia Telangiectasia (AT) *
5.6.5. Diagnosed Cases of the Ataxia Telangiectasia (AT)
5.6.6. Treatable Cases of the Ataxia Telangiectasia (AT)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Ataxia Telangiectasia (AT)
5.7.3. Sub-Type Specific cases of the Ataxia Telangiectasia (AT) *
5.7.4. Sex- Specific Cases of the Ataxia Telangiectasia (AT) *
5.7.5. Diagnosed Cases of the Ataxia Telangiectasia (AT)
5.7.6. Treatable Cases of the Ataxia Telangiectasia (AT)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Ataxia Telangiectasia (AT)
5.8.3. Sub-Type Specific cases of the Ataxia Telangiectasia (AT) *
5.8.4. Sex- Specific Cases of the Ataxia Telangiectasia (AT) *
5.8.5. Diagnosed Cases of the Ataxia Telangiectasia (AT)
5.8.6. Treatable Cases of the Ataxia Telangiectasia (AT)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Ataxia Telangiectasia (AT)
5.9.3. Sub-Type Specific cases of the Ataxia Telangiectasia (AT) *
5.9.4. Sex- Specific Cases of the Ataxia Telangiectasia (AT) *
5.9.5. Diagnosed Cases of the Ataxia Telangiectasia (AT)
5.9.6. Treatable Cases of the Ataxia Telangiectasia (AT)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Ataxia Telangiectasia (AT)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Ataxia Telangiectasia (AT)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Ataxia Telangiectasia (AT) : 7MM Market Analysis
12.1. 7MM Market Size of Ataxia Telangiectasia (AT)
12.2. 7MM Percentage Share of drugs marketed for Ataxia Telangiectasia (AT)
12.3. 7MM Market Sales of Ataxia Telangiectasia (AT) by Products
13. Ataxia Telangiectasia (AT) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Ataxia Telangiectasia (AT) in United States
13.1.2. Percentage Share of drugs marketed for Ataxia Telangiectasia (AT) in United States
13.1.3. Market Sales of Ataxia Telangiectasia (AT) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Ataxia Telangiectasia (AT) in Germany
13.2.1.2. Percentage Share of drugs marketed for Ataxia Telangiectasia (AT) in Germany
13.2.1.3. Market Sales of Ataxia Telangiectasia (AT) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Ataxia Telangiectasia (AT) in France
13.2.2.2. Percentage Share of drugs marketed for Ataxia Telangiectasia (AT) in France
13.2.2.3. Market Sales of Ataxia Telangiectasia (AT) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Ataxia Telangiectasia (AT) in Italy
13.2.3.2. Percentage Share of drugs marketed for Ataxia Telangiectasia (AT) in Italy
13.2.3.3. Market Sales of Ataxia Telangiectasia (AT) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Ataxia Telangiectasia (AT) in Spain
13.2.4.2. Percentage Share of drugs marketed for Ataxia Telangiectasia (AT) in Spain
13.2.4.3. Market Sales of Ataxia Telangiectasia (AT) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Ataxia Telangiectasia (AT) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Ataxia Telangiectasia (AT) in United Kingdom
13.2.5.3. Market Sales of Ataxia Telangiectasia (AT) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Ataxia Telangiectasia (AT) in Japan
13.3.2. Percentage Share of drugs marketed for Ataxia Telangiectasia (AT) in Japan
13.3.3. Market Sales of Ataxia Telangiectasia (AT) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. Capabilities
19. Disclaimer
List of Figures
Figure 1: Total Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Figure 6: Diagnosed Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Figure 7: Treatable Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Figure 12: Treatable Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Figure 15: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Figure 16: Diagnosed Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Figure 17: Treatable Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Figure 22: Treatable Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Figure 27: Treatable Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Figure 31: Diagnosed Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Figure 32: Treatable Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Figure 37: Treatable Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 42:7MM- Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 45: United States-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 48: Germany-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 51: France-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 54: Italy-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 57: Spain-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 60:UK-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Figure 63: Japan-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
List of Tables
Table 1: Total Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in 7MM
Table 2: Total Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Table 5: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Table 6: Diagnosed Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Table 7: Treatable Cases of the Ataxia Telangiectasia (AT) in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Table 11: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Table 12: Treatable Cases of the Ataxia Telangiectasia (AT) in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Table 14: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Table 15: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Table 16: Diagnosed Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Table 17: Treatable Cases of the Ataxia Telangiectasia (AT) in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Table 21: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Table 22: Treatable Cases of the Ataxia Telangiectasia (AT) in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Table 26: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Table 27: Treatable Cases of the Ataxia Telangiectasia (AT) in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Table 30: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Table 31: Diagnosed Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Table 32: Treatable Cases of the Ataxia Telangiectasia (AT) in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Table 36: Diagnosed Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Table 37: Treatable Cases of the Ataxia Telangiectasia (AT) in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 42:7MM- Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 45: United States-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 48: Germany-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 51: France-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 54: Italy-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 57: Spain-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 60:UK-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Ataxia Telangiectasia (AT) in USD MM (2017-2028)
Table 63: Japan-Market Share Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Ataxia Telangiectasia (AT) by Therapies in USD MM (2017-2028)